查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717916

溶小体贮积症市场（按疾病类型、治疗类型、治疗应用和最终用户划分）—2025 年至 2030 年全球预测

Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

溶小体贮积症市场预计到 2024 年将达到 101.7 亿美元，到 2025 年将达到 110.1 亿美元，到 2030 年将达到 164.9 亿美元，复合年增长率为 8.38%。

主要市场统计数据
基准年2024年 101.7亿美元
预计2025年 110.1亿美元
预测年份 2030 164.9亿美元
复合年增长率（%） 8.38%

溶小体贮积症的研究是现代医学和生物技术的重要前沿领域。这些遗传性代谢紊乱导致未消化的基材在细胞溶酶体内积累，长期以来一直为临床和科学带来挑战。最近的研究趋势和技术进步正在提高我们对疾病机制的理解并加速创新治疗方法的发展。当全球医疗保健界面临这种情况时，彻底的市场分析、策略性投资和研究合作的重要性变得更加明显。

此外，这项深入研究不仅概述了治疗方案和诊断方法的现状，而且还揭示了正在重新定义竞争格局的新兴趋势和变革性转变。透过严格的分析，该报告将成为相关人员寻求驾驭复杂市场动态的重要指南，从突破性的基因疗法到传统的酵素干预，最终旨在改善全球患者的治疗效果。

随着研究人员、临床医生和决策者的共同努力，将不断发展的临床数据与创新治疗方法结合变得前所未有的重要。本报告的总体目标是提供一份权威的蓝图，阐明不断发展的疾病治疗领域中的机会和挑战，并提供可行的见解，以推进溶酶体储存症领域的临床实践和经济战略。

改变溶小体贮积症格局的变革

生物医学研究和技术创新的最新进展正在大幅改变溶小体贮积症的格局。从历史上看，治疗仅限于安宁疗护和症状管理。然而，如今分子生物学和标靶治疗方法的令人兴奋的突破正在彻底改变患者护理。这种转变为精准医疗策略铺平了道路，该策略可根据个别患者特征和特定疾病机制量身定制治疗方案。

次世代定序和先进影像技术的采用提高了我们在早期阶段诊断这些疾病的能力，此时治疗性介入可以产生最大的影响。更重要的是，这些技术创新促进了治疗模式的转变。基因治疗的整合、酵素替代疗法的改进以及造血干细胞移植的探索共同重新定义了临床实践中的护理标准。

此外，新型化合物和治疗平台的出现为治疗与溶小体贮积症相关的复杂性引入了多方面的方法来应对。这些发展不仅改善了患者的治疗效果，也促使人们重新评估市场动态、监管环境和研究管道。从传统药物开发到客製化、通路特异性治疗方法的演变代表着该领域的向前迈出了一步，为以多学科合作和前所未有的临床突破为特征的时代铺平了道路。

随着产业的不断发展，决策者必须跟上这些变革，以便在日益由快速的技术进步和对疾病病理学的更深入了解所定义的市场中策略性地定位自己。

利用市场区隔的洞察来客製化您的市场策略

溶小体贮积症市场的细分提供了对各个子区隔的详细观点，这些细分市场在理解市场趋势和投资潜力方面发挥关键作用。在疾病类型方面，我们对法布瑞氏症、高雪氏症、韩特氏症症候群、黏多醣症、尼曼匹克症和庞贝氏症等各种疾病进行了全面的回顾。每种疾病都有不同的临床症状和治疗挑战，并且需要不同的诊断和治疗方法。

治疗方法的评估将分析酵素替代疗法（进一步细分和研究，包括阿加糖酶β、阿糖苷酶和Glucosidaseα）、基因治疗、造血干细胞移植（分为同种异体移植和自体移植）和基材减少疗法之间的动态交互作用。这些治疗方法的演变反映了强大的创新管道，其疗效和安全性不断与传统治疗方法进行比较。这种分类分析不仅突显了可用治疗方案的多样性，而且突显了每个类别内治疗性介入的演变。

此外，为了反映溶小体贮积症对患者的多方面影响，市场根据治疗应用进行细分。对心血管疾病、中枢神经系统疾病、血液疾病、肺部併发症和骨骼畸形等领域的分析将使相关人员能够确定治疗性介入能够提供最大临床益处和市场机会的领域。了解特定的临床关注领域和治疗应用使公司能够优化研发策略并对重要的健康结果进行基准测试。

最后，一个关键的细分要素是最终用户分析。它研究学术研究机构、生物製药公司、医院和专科诊所的市场动态。从早期研究到临床应用，每个环节都是疾病管理网路中独特的节点。从这些细分参数中获得的详细见解可以实现资源的策略性调整，从而指导临床研究和投资决策，以解决疾病病理学和组织创新能力的细微差别。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 溶小体贮积症的盛行率
      • 疾病早期诊断和治疗的趋势
      • 增加酵素替代疗法的使用
    • 限制因素
      • 治疗费用高且治疗机会有限
    • 机会
      • 治疗溶小体疾病的新兴个人化医疗方法
      • 溶小体储积症的基因编辑与基因治疗进展
    • 任务
      • 溶小体储存药物核准的严格法规结构
  • 市场区隔分析
    • 疾病类型：扩展Chaperone疗法的研发管线，以应对法布瑞氏症的不同突变情况
    • 应用：由于许多 LSD 的心臟併发症性质严重，将溶小体贮积症的应用扩展到心血管系统，
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 溶小体贮积症市场（依疾病类型）

  • 法布瑞氏症
  • 高雪氏症
  • 韩特氏症
  • 黏多醣症
  • 尼曼匹克病
  • 庞贝氏症

7. 溶小体贮积症市场（依治疗类型）

  • 酵素替代疗法
    • 阿加糖酶β
    • 阿糖苷酶
    • Glucosidase酶α
  • 基因治疗
  • 造血干细胞移植
    • 同种异体移植
    • 自体移植
  • 基材还原疗法

8. 溶小体贮积症市场（依治疗应用）

  • 心血管疾病
  • 中枢神经系统疾病
  • 血液系统疾病
  • 肺部併发症
  • 骨骼畸形

9. 溶小体贮积症市场（依最终用户）

  • 学术研究所
  • 生物製药公司
  • 医院
  • 专科诊所

10. 美洲溶小体贮积症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11.亚太溶小体贮积症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲的溶小体贮积症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics,Inc.
  • ArmaGen, Inc.
  • BioMarin Pharmaceutical, Inc.
  • CHIESI USA, Inc.
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Homology Medicines, Inc.
  • Horizon Pharma PLC
  • Idorsia Pharmaceuticals Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics Limited
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • Zevra Therapeutics,Inc.
Product Code: MRR-DD0700E81E5B

The Lysosomal Storage Diseases Market was valued at USD 10.17 billion in 2024 and is projected to grow to USD 11.01 billion in 2025, with a CAGR of 8.38%, reaching USD 16.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.17 billion
Estimated Year [2025] USD 11.01 billion
Forecast Year [2030] USD 16.49 billion
CAGR (%) 8.38%

The study of lysosomal storage diseases represents a critical frontier in modern medicine and biotechnology. These inherited metabolic disorders, which result in the accumulation of undigested substrates within cellular lysosomes, have long presented both clinical and scientific challenges. In recent years, enhanced research and technological advances have catalyzed a deeper understanding of disease mechanisms and accelerated the development of innovative therapies. As the global healthcare community confronts these conditions, the importance of thorough market analysis, strategic investment, and collaborative research has become increasingly clear.

Moreover, this detailed examination not only outlines the current state of therapeutic options and diagnostic methods, but it also sheds light on emerging trends and transformative shifts that are redefining the competitive landscape. Through rigorous analysis, the report positions itself as an indispensable guide for stakeholders seeking to navigate complex market dynamics, from groundbreaking gene therapies to traditional enzymatic interventions, ultimately aiming to improve patient outcomes worldwide.

As researchers, clinicians, and decision-makers work together, the integration of evolving clinical data and innovative treatment modalities is more critical than ever. The overarching goal of this report is to deliver an authoritative roadmap that highlights the opportunities and challenges within the evolving disease treatment environment, providing actionable insights tailored to advance clinical practice and economic strategies in the realm of lysosomal storage diseases.

Transformative Shifts Reshaping the Lysosomal Storage Diseases Landscape

Recent advancements in biomedical research and technological innovation have dramatically transformed the landscape of lysosomal storage diseases. Historically, treatments were limited to palliative care and symptom management. Today, however, transformative breakthroughs in molecular biology and targeted therapeutic approaches are revolutionizing patient care. These shifts have paved the way for precision medicine strategies, where treatments are tailored to individual patient profiles and specific pathogenetic mechanisms.

The adoption of next-generation sequencing and advanced imaging techniques has enhanced our ability to diagnose these disorders at earlier stages, when therapeutic interventions can have the most profound impact. More importantly, these innovations have spurred a revolution in treatment paradigms. The integration of gene therapy, improvements in enzyme replacement therapy, and the exploration of hematopoietic stem cell transplants have collectively redefined standard practices in clinical settings.

Furthermore, the emergence of novel compounds and therapeutic platforms has introduced a multi-dimensional approach to managing the complexities associated with lysosomal storage diseases. Such developments have not only improved patient outcomes but have also driven a broader re-assessment of market dynamics, regulatory landscapes, and research pipelines. The evolution from conventional drug development to customized, pathway-specific therapies is emblematic of the sector's forward momentum, paving the way for an era characterized by cross-disciplinary collaboration and unprecedented clinical breakthroughs.

As the industry continues to evolve, decision-makers must stay abreast of these transformative changes to strategically position themselves in a market that is increasingly defined by rapid technological advancements and a deepened understanding of disease pathology.

Key Segmentation Insights for Tailored Market Strategies

The segmentation of the lysosomal storage diseases market provides a granular perspective on the various sub-segments that play a crucial role in understanding market trends and investment potential. From a disease type perspective, the market is comprehensively studied across a spectrum of conditions, including Fabry Disease, Gaucher Disease, Hunter Syndrome, Mucopolysaccharidosis, Niemann-Pick Disease, and Pompe Disease. These conditions, each with distinct clinical manifestations and treatment challenges, require tailored approaches to diagnosis and therapy.

When evaluating treatment modalities, the analysis explores the dynamic interplay between Enzyme Replacement Therapy (which itself is investigated through further subdivisions such as Agalsidase Beta, Alglucerase, and Alglucosidase Alfa), Gene Therapy, Hematopoietic Stem Cell Transplant (divided into Allogeneic Transplant and Autologous Transplant), and Substrate Reduction Therapy. The evolution of these therapies reflects a robust pipeline of innovation, where the efficacy and safety profiles are continually benchmarked against traditional treatment regimens. This segmented analysis not only underscores the diversity of treatment options available but also highlights the evolving nature of therapeutic interventions within each category.

Additionally, the market is segmented based on therapeutic application, reflecting the multifaceted ways in which lysosomal storage diseases affect patients. Analysis across areas such as cardiovascular involvement, central nervous system involvement, hematological disorders, pulmonary complications, and skeletal deformities enables stakeholders to pinpoint where therapeutic interventions yield the highest clinical benefit and market opportunity. By understanding the specific areas of clinical concern and treatment application, companies can optimize their research and development strategies to benchmark significant health outcomes.

Lastly, an important segmentation factor is the end-user analysis. This examines market dynamics across academic and research institutes, biopharmaceutical companies, hospitals, and specialty clinics. Each of these segments represents a unique node in the network of disease management, from early-stage research to clinical application. The detailed insights derived from these segmentation parameters enable strategic alignment of resources, guiding clinical research and investment decisions in a way that addresses the nuances of both disease pathology and organizational capacity for innovation.

Based on Disease Type, market is studied across Fabry Disease, Gaucher Disease, Hunter Syndrome, Mucopolysaccharidosis, Niemann-Pick Disease, and Pompe Disease.

Based on Treatment Type, market is studied across Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant, and Substrate Reduction Therapy. The Enzyme Replacement Therapy is further studied across Agalsidase Beta, Alglucerase, and Alglucosidase Alfa. The Hematopoietic Stem Cell Transplant is further studied across Allogeneic Transplant and Autologous Transplant.

Based on Therapeutic Application, market is studied across Cardiovascular Involvement, Central Nervous System Involvement, Hematological Disorders, Pulmonary Complications, and Skeletal Deformities.

Based on End-User, market is studied across Academic & Research Institutes, Biopharmaceutical Companies, Hospitals, and Specialty Clinics.

Regional Dynamics Driving Market Penetration and Growth

Geographical segmentation reveals distinct regional dynamics that shape the market landscape and inform strategic expansion efforts. In the Americas, a combination of robust healthcare infrastructure, advanced research capabilities, and high investment in clinical trials has yielded significant innovations in the treatment of lysosomal storage diseases. The region is a hotbed of clinical research and regulatory advancements, ensuring rapid patient access to emerging therapies while also providing a supportive environment for biotech startups and established pharmaceutical companies.

Meanwhile, the region encompassing Europe, the Middle East, and Africa presents a diverse and complex market scenario. European countries, in particular, benefit from a mature regulatory framework and strong public-private partnerships that drive research and development in rare diseases. The simultaneous development of regional collaborations and initiatives to address healthcare disparities has spurred the adoption of cutting-edge therapies. In the Middle East and Africa, increasing healthcare expenditures and a growing recognition of the need for advanced diagnostic tools are gradually building the necessary infrastructure to support significant market growth.

The Asia-Pacific region continues to emerge as a strategic growth driver, characterized by rapid economic development and a burgeoning biopharmaceutical sector. This region is notable for its accelerated investment in medical research and infrastructure expansion, leading to faster adoption of innovative treatments. Additionally, a growing patient population combined with increasing awareness about lysosomal storage diseases is elevating market demand. The convergence of these factors creates a unique opportunity for market entrants to tailor their strategies, blending advanced research with region-specific healthcare needs and economic considerations.

Thus, regional insights not only highlight the disparities and opportunities across different geographies but also underscore the importance of a localized approach for market penetration and sustainable growth in the domain of lysosomal storage diseases.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders at the Forefront of Innovation

The competitive landscape in the treatment and management of lysosomal storage diseases is marked by the involvement of several pioneering companies. Industry players such as Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., and ArmaGen, Inc. are driving venture investments and fuel innovative research pipelines to combat the complexities of these disorders. These organizations, along with BioMarin Pharmaceutical, Inc., CHIESI USA, Inc., and Denali Therapeutics Inc., have made significant inroads by leveraging advanced therapeutic platforms and clinical trial data.

Other standout companies, including Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, and Idorsia Pharmaceuticals Ltd., are investing heavily in translational research, ensuring that discoveries at the bench are seamlessly transitioned into the clinic. The impact of these advancements is further amplified by the strategic partnerships forged with JCR Pharmaceuticals Co., Ltd., Neurogene Inc., and Novartis AG, which contribute to a dynamic ecosystem of innovation and market growth. Moreover, firms like Orchard Therapeutics Limited, Pfizer Inc., Protalix Biotherapeutics Inc., and Sangamo Therapeutics, Inc. are actively involved in developing next-generation therapies that promise to alter the treatment paradigm significantly.

Additional contributions come from Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., and Zevra Therapeutics, Inc. Each of these industry leaders brings unique strengths to the table, from robust financial resources and expansive research capabilities to a deep portfolio of clinical innovations. Their strategic investments in research and development have not only enhanced therapeutic efficacy but also ensured a collaborative approach to addressing regulatory challenges and market uncertainties.

Collectively, these companies are setting new benchmarks in the field of lysosomal storage diseases, driving forward a cycle of continuous improvement and market expansion. Their commitment to addressing unmet medical needs and improving patient outcomes is reshaping the competitive landscape in ways that promise long-term benefits for both investors and healthcare providers alike.

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics,Inc., ArmaGen, Inc., BioMarin Pharmaceutical, Inc., CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix Biotherapeutics Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., and Zevra Therapeutics,Inc.. Actionable Recommendations for Strategic Market Positioning

To capitalize on the rapid pace of innovation in lysosomal storage diseases, industry leaders must adopt a proactive and multidimensional strategy. First and foremost, it is essential to invest in research and development initiatives that not only target existing clinical challenges but also explore the potential of emerging therapeutic modalities such as gene therapy and advanced enzyme replacement treatments. Embracing new technologies and integrating big data analytics can streamline clinical trial processes and ensure that therapies are optimized for both efficacy and safety.

Companies should also consider strategic alliances and collaborative research efforts with academic institutions and clinical research organizations. Such partnerships can help bridge the gap between laboratory discoveries and their translation into market-ready products. By sharing resources and expertise, entities can accelerate innovation cycles and reduce the inherent risks associated with developing therapies for rare diseases.

Furthermore, decision-makers need to be nimble in adapting to regulatory changes and aligning their market strategies accordingly. Proactive engagement with regulatory bodies, coupled with a willingness to participate in pilot programs and innovative pricing models, will be critical in addressing market uncertainties and ensuring timely product launches. Investment in robust data collection and outcome measurement systems will enable companies to demonstrably showcase the value of their treatments, thereby gaining an edge over competitors in an increasingly crowded market.

Lastly, it is imperative to maintain a patient-centric approach. Understanding the nuanced needs of different patient demographics and tailoring therapeutic solutions accordingly can significantly boost market penetration. Whether through enhancing patient support programs or investing in community-based initiatives, the alignment of corporate goals with patient well-being will continue to be a key driver of sustainable growth in the field.

By implementing these actionable recommendations, industry leaders can not only navigate the complexities of market volatility but also secure a competitive advantage in a rapidly evolving therapeutic landscape.

Conclusion: Charting a Sustainable Future in Lysosomal Storage Diseases

In conclusion, the landscape of lysosomal storage diseases is experiencing an unprecedented phase of transformation. With advancements in diagnostic technologies and the emergence of innovative therapeutic platforms, the market is poised to not only improve the quality of life for patients but also drive significant returns for investors and stakeholders alike. The multifaceted analysis presented in this executive summary - which spans disease type differentiation, evolving treatment options, therapeutic application, and end-user dynamics - underscores the importance of a detailed and proactive approach in tackling this complex healthcare challenge.

The integration of transformative technologies, strategic regional insights, and a dedicated focus on high-potential market segments forms the cornerstone of future success in this domain. As the competitive landscape becomes more dynamic, it is imperative that industry leaders continue to adapt and innovate, aligning their research and development initiatives with evolving clinical needs and market trends.

Ultimately, the journey toward more effective management of lysosomal storage diseases hinges on the collective efforts of researchers, clinicians, and policymakers. By fostering a culture of innovation and embracing collaborative strategies, stakeholders can ensure that significant progress is not only maintained but accelerated in the coming years. This report offers a comprehensive framework for navigating these challenges and seizing the opportunities that lie ahead, paving the way for a more sustainable and patient-centered future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of lysosomal storage disorders
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Increasing use of enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limiting accessibility
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of personalized medicine approach to treat lysosomal
      • 5.1.3.2. Advancements in gene editing technologies and gene therapies for lysosomal storage disorder
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pipeline of chaperone therapies to address varying mutational profiles in fabry disease
    • 5.2.2. Application: Expanding application of lysosomal storage diseases in cardiovascular Involvement due to the critical nature of cardiac complications in numerous LSDs,
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lysosomal Storage Diseases Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Fabry Disease
  • 6.3. Gaucher Disease
  • 6.4. Hunter Syndrome
  • 6.5. Mucopolysaccharidosis
  • 6.6. Niemann-Pick Disease
  • 6.7. Pompe Disease

7. Lysosomal Storage Diseases Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Enzyme Replacement Therapy
    • 7.2.1. Agalsidase Beta
    • 7.2.2. Alglucerase
    • 7.2.3. Alglucosidase Alfa
  • 7.3. Gene Therapy
  • 7.4. Hematopoietic Stem Cell Transplant
    • 7.4.1. Allogeneic Transplant
    • 7.4.2. Autologous Transplant
  • 7.5. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Involvement
  • 8.3. Central Nervous System Involvement
  • 8.4. Hematological Disorders
  • 8.5. Pulmonary Complications
  • 8.6. Skeletal Deformities

9. Lysosomal Storage Diseases Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biopharmaceutical Companies
  • 9.4. Hospitals
  • 9.5. Specialty Clinics

10. Americas Lysosomal Storage Diseases Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lysosomal Storage Diseases Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lysosomal Storage Diseases Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Zevra Therapeutics secures FDA approval for Miplyffa targeting Niemann-Pick Disease Type C
    • 13.3.2. Hanmi Pharmaceutical and GC Biopharma advance next-gen Fabry disease treatment with FDA-cleared once-monthly injection
    • 13.3.3. CENTOGENE and Takeda strengthen global partnership to enhance genetic testing for lysosomal storage disorders
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics,Inc.
  • 4. ArmaGen, Inc.
  • 5. BioMarin Pharmaceutical, Inc.
  • 6. CHIESI USA, Inc.
  • 7. Denali Therapeutics Inc.
  • 8. Freeline Therapeutics
  • 9. Homology Medicines, Inc.
  • 10. Horizon Pharma PLC
  • 11. Idorsia Pharmaceuticals Ltd.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Neurogene Inc.
  • 14. Novartis AG
  • 15. Orchard Therapeutics Limited
  • 16. Pfizer Inc.
  • 17. Protalix Biotherapeutics Inc.
  • 18. Sangamo Therapeutics, Inc.
  • 19. Sanofi S.A.
  • 20. Spark Therapeutics, Inc.
  • 21. Swedish Orphan Biovitrum AB
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Ultragenyx Pharmaceutical Inc.
  • 24. Zevra Therapeutics,Inc.

LIST OF FIGURES

  • FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET MULTI-CURRENCY
  • FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET MULTI-LANGUAGE
  • FIGURE 3. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 4. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HUNTER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY NIEMANN-PICK DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALGLUCERASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CARDIOVASCULAR INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY PULMONARY COMPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SKELETAL DEFORMITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 288. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024